Condition: Ganglioneuroblastoma · Ganglioneuroblastoma, Nodular · Neuroblastoma · Sponsor: Children's Oncology Group
This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Children's Hospital of Alabama | Birmingham, Alabama, United States | Recruiting |
| Phoenix Childrens Hospital | Phoenix, Arizona, United States | Recruiting |
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | Recruiting |
| Kaiser Permanente Downey Medical Center | Downey, California, United States | Recruiting |
| Loma Linda University Medical Center | Loma Linda, California, United States | Recruiting |
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| Mattel Children's Hospital UCLA | Los Angeles, California, United States | Recruiting |
| Valley Children's Hospital | Madera, California, United States | Recruiting |
| Kaiser Permanente-Oakland | Oakland, California, United States | Recruiting |
| Children's Hospital of Orange County | Orange, California, United States | Recruiting |
| Lucile Packard Children's Hospital Stanford University | Palo Alto, California, United States | Recruiting |
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
+ 150 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03126916